Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 30;15(11):2179.
doi: 10.3390/v15112179.

Suitable Disinfectants with Proven Efficacy for Genetically Modified Viruses and Viral Vectors

Affiliations
Review

Suitable Disinfectants with Proven Efficacy for Genetically Modified Viruses and Viral Vectors

Maren Eggers et al. Viruses. .

Abstract

Viral disinfection is important for medical facilities, the food industry, and the veterinary field, especially in terms of controlling virus outbreaks. Therefore, standardized methods and activity levels are available for these areas. Usually, disinfectants used in these areas are characterized by their activity against test organisms (i.e., viruses, bacteria, and/or yeasts). This activity is usually determined using a suspension test in which the test organism is incubated with the respective disinfectant in solution to assess its bactericidal, yeasticidal, or virucidal activity. In addition, carrier methods that more closely reflect real-world applications have been developed, in which microorganisms are applied to the surface of a carrier (e.g., stainless steel frosted glass, or polyvinyl chloride (PVC)) and then dried. However, to date, no standardized methods have become available for addressing genetically modified vectors or disinfection-resistant oncolytic viruses such as the H1-parvovirus. Particularly, such non-enveloped viruses, which are highly resistant to disinfectants, are not taken into account in European standards. This article proposes a new activity claim known as "virucidal activity PLUS", summarizes the available methods for evaluating the virucidal activity of chemical disinfectants against genetically modified organisms (GMOs) using current European standards, including the activity against highly resistant parvoviridae such as the adeno-associated virus (AAV), and provides guidance on the selection of disinfectants for pharmaceutical manufacturers, laboratories, and clinical users.

Keywords: AAV; disinfection; genetically modified organisms (GMOs); suspension tests; vector; viral vectors; virucidal activity; virus inactivation.

PubMed Disclaimer

Conflict of interest statement

The author I.R. is an employee of the company Boehringer Ingelheim Therapeutics GmbH and declares that no conflicts of interest exist regarding the data presented here. All other authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Tarka P., Nitsch-Osuch A. Evaluating the Virucidal Activity of Disinfectants According to European Union Standards. Viruses. 2021;13:534. doi: 10.3390/v13040534. - DOI - PMC - PubMed
    1. Eggers M., Schwebke I., Suchomel M., Fotheringham V., Gebel J., Meyer B., Morace G., Roedger H.J., Roques C., Visa P., et al. The European tiered approach for virucidal efficacy testing—Rationale for rapidly selecting disinfectants against emerging and re-emerging viral diseases. Eurosurveillance. 2021;26:2000708. doi: 10.2807/1560-7917.ES.2021.26.3.2000708. - DOI - PMC - PubMed
    1. Hajda J., Leuchs B., Angelova A.L., Frehtman V., Rommelaere J., Mertens M., Pilz M., Kieser M., Krebs O., Dahm M., et al. Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Clin. Cancer Res. 2021;27:5546–5556. doi: 10.1158/1078-0432.CCR-21-1020. - DOI - PubMed
    1. Chulpanova D.S., Solovyeva V.V., Kitaeva K.V., Dunham S.P., Khaiboullina S.F., Rizvanov A.A. Recombinant Viruses for Cancer Therapy. Biomedicines. 2018;6:94. doi: 10.3390/biomedicines6040094. - DOI - PMC - PubMed
    1. Jhawar S.R., Thandoni A., Bommareddy P.K., Hassan S., Kohlhapp F.J., Goyal S., Schenkel J.M., Silk A.W., Zloza A. Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies. Front. Oncol. 2017;7:202. doi: 10.3389/fonc.2017.00202. - DOI - PMC - PubMed

LinkOut - more resources